A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: Development and validation studies

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 676-685

  Rini, Brian ^a   Goddard, Audrey ^b   Knezevic, Dejan ^b   Maddala, Tara ^b   Zhou, Ming ^c   Aydin, Hakan ^d   Campbell, Steven ^a   Elson, Paul ^a   Koscielny, Serge ^e   Lopatin, Margarita ^b   Svedman, Christer ^b   Martini, Jean Francois ^f   Williams, J Andrew ^f   Verkarre, Virginie ^g   Radulescu, Camelia ^h   Neuzillet, Yann ^h   Hemmerlé, Isabelle ^h   Timsit, Marc Olivier ⁱ   Tsiatis, Athanasios C ^b   Bonham, Michael ^b   Lebret, Thierry ^h   Mejean, Arnaud ⁱ   Escudier, Bernard ^e   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b Genomic Health Inc   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PFIZER INC   (United States)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h FOCH HOSPITAL   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; VALIDATION STUDY; BIOSYNTHESIS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS;

TUMOR PROTEIN;

AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS;

EID: 84930277863     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70167-1     Document Type: Article

References (49)

1. Lipworth L, Tarone RE, McLaughlin JK The epidemiology of renal cell carcinoma. J Urol 2006, 176:2353-2358.
2. Moore LE, Nickerson ML, Brennan P, et al. Von Hippel-Lindau inactivation in sporadic clear cell renal cancer: associations with germline polymorphisms and etiologic risk factors. PLoS Genet 2011, 7:e1002312.
3. Hartmann J, Bokemeyer C Chemotherapy for renal cell carcinoma. Anticancer Res 1999, 19(2C):1541-1543.
4. Logan JE, Rampersaud EN, Sonn GA, et al. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol 2012, 14:65-78.
5. Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 2013, 40:482-491.
6. Rini BI, Campbell SC, Escudier B Renal cell carcinoma. Lancet 2009, 373:1119-1132.
7. Edge SB, Compton CC The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
8. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.
9. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671.
10. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
11. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
12. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol 2011, 35:1134-1139.
13. Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005, 103:68-75.
14. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014, 66:550-560.
15. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010, 28:3937-3944.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
17. Clinical Practice Guidelines in Oncology: breast cancer (version 3.2014) NCCN, (accessed March 2, 2015). http://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf.
18. Eble JN, Sauter G, Epstein J, Sesterhenn IA World Health Organization Classification of Tumors. Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC Press, Lyon.
19. Greene F, Page DL, Fleming I, et al. The American Joint Committee on Cancer: Cancer Staging Manual 2002, Springer-Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong. Sixth Edition.
20. Fuhrman SA, Lasky LC, Limas C Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
21. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005, 104:511-520.
22. Clark-Langone K, Wu J, Sangli C, et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genom 2007, 8:279.
23. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genom 2013, 14:690.
24. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42.
25. Storey J A direct approach to false discovery rates. J R Stat Soc B 2002, 64:479-498.
26. Crager MR Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the mean. Stat Med 2010, 29:33-45.
27. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 8:515-526.
28. Therneau TM, Grambsch PM Modeling survival data: extending the Cox model 2001, Springer, New York.
29. Belldegrun A, Chamie K, Kloepfer P, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-results and implications for adjuvant clinical trials. J Clin Oncol 2013, 31(suppl). abstr 4507.
30. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014, 46:225-233.
31. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
32. Isbarn H, Patard JJ, Lughezzani G, et al. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. Urology 2010, 75:1378-1384.
33. Klatte T, Said JW, de Martino M, et al. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol 2009, 181:1558-1564.
34. Daugherty M, Bratslavsky G Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage In patients between the ages of 20 and 44 years with renal cell carcinomas (
35. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010, 1:152-163.
36. Kosari F, Parker AS, Kube DM, et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005, 11:5128-5139.
37. Yao M, Huang Y, Shioi K, et al. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer 2008, 123:1126-1132.
38. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004, 171:2171-2175.
39. Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006, 97:780-786.
40. Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004, 22:2371-2378.
41. Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014, 66:77-84.
42. Blattner M, Lee DJ, O'Reilly C, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 2014, 16:14-20.
43. Motzer RJ, Hutson TE, Hudes GR, et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol 2014, 74:739-750.
44. Simon RM, Paik S, Hayes DF Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452.
45. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
46. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.
47. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat NICE diagnostics guidance, (accessed May 4, 2015). http://www.nice.org.uk/guidance/dg10.
48. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009, 55:287-295.
49. Vrdoljak E, Rini B, Schmidinger M, et al. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 2013, 24:431-440.